Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer : a single-center experience and review of literature
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: https://doi.org/10.21037/jgo-22-632
In: : AME Publishing Company, 2023
In: Journal of Gastrointestinal Oncology, 2023, vol. 14, 1, S. 352-365
- Ereignis
-
Veröffentlichung
- (wo)
-
Bonn
- (wer)
-
Universitäts- und Landesbibliothek Bonn
- (wann)
-
2023
- Urheber
-
Möhring, Christian
Frontado Graffe, Freddy José
Bartels, Alexandra
Sadeghlar, Farsaneh
Zhou, Taotao
Mahn, Robert
Marinova, Milka
Feldmann, Georg
Brossart, Peter
Glowka, Tim
Kalff, Jörg
Strassburg, Christian
Gonzalez-Carmona, Maria
- Handle
-
20.500.11811/10815
- URN
-
urn:nbn:de:101:1-2023050402562734875441
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Möhring, Christian
- Frontado Graffe, Freddy José
- Bartels, Alexandra
- Sadeghlar, Farsaneh
- Zhou, Taotao
- Mahn, Robert
- Marinova, Milka
- Feldmann, Georg
- Brossart, Peter
- Glowka, Tim
- Kalff, Jörg
- Strassburg, Christian
- Gonzalez-Carmona, Maria
- Universitäts- und Landesbibliothek Bonn
Entstanden
- 2023
Ähnliche Objekte (12)
Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
Liposomales Irinotecan (nal-IRI, Onivyde) : eine neue Therapieoption zur Behandlung des metastasierten Pankreaskarzinoms
Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers
Second-line Therapien bei malignen biliären Tumoren
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
Sirolimus as a second-line treatment for Graves’ orbitopathy
Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics
Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel
Comparison of first-line and second-line terlipressin versus sole norepinephrine in fulminant ovine septic shock
Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
Liposomales Irinotecan (nal-IRI, Onivyde) : eine neue Therapieoption zur Behandlung des metastasierten Pankreaskarzinoms
Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers
Second-line Therapien bei malignen biliären Tumoren
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
Sirolimus as a second-line treatment for Graves’ orbitopathy
Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics
Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel
Comparison of first-line and second-line terlipressin versus sole norepinephrine in fulminant ovine septic shock
Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
Liposomales Irinotecan (nal-IRI, Onivyde) : eine neue Therapieoption zur Behandlung des metastasierten Pankreaskarzinoms
Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers
Second-line Therapien bei malignen biliären Tumoren
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
Sirolimus as a second-line treatment for Graves’ orbitopathy
Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics
Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel